Tighter oversight of manufacturers pricing policies and the competitive environment Its unseemly (polite word choice) that the CEO of Lilly, Dave Ricks, is able to rake in total compensation of $114 million in 2024 while at the same time acknowledging that the price his company charges for Zepbound is too high. Unseemly, because his payday was fueled by Lilly making more than $10 billion in profit from GLP-1s in 2024 alone
A study also showed that the composition of the microbiome was more stable with age, with more gram-positive (G+) bacteria and fewer G- bacteria, regardless of disease state (19)
However, Tirzepatide may not be suitable for everyone
estimated ~41% direct, weight-loss-independent effect.) Wang L, Xu R, Kaelber DC, Berger NA
References 1 Al-kuraishyH
Were also running one of the first clinical trials studying Microdosing GLP-1 for longevity, exploring how it improves inflammation, pain, brain fog, metabolic health, and advanced biomarkers of biological aging